Tag Archives: Becton Dickinson

Aug. 1, 2023—BD announced FDA 510(k) clearance of its BD Respiratory Viral Panel for the BD Max system.

May 23, 2022—BD announced the U.S. launch of its fully automated, high-throughput infectious disease molecular diagnostics platform, the BD COR MX.

July 28, 2020—Becton Dickinson received approval for a premarket approval supplement from the FDA for an expanded version of its BD Onclarity HPV Assay.